Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice
| Autor: | J. W. Smith, R. Dean, Marilyn S. Bartlett, Margaret M. Shaw, Chao-Hung Lee, Sherry F. Queener, T. D. Edlind |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_treatment
Biology Pharmacology Albendazole Dexamethasone Mice medicine Animals Pharmacology (medical) Anthelmintic Immunosuppression Therapy Mice Inbred BALB C Chemotherapy Pneumocystis Immunosuppression medicine.disease Pneumonia Infectious Diseases Pneumocystis carinii Monoclonal Immunology Female Research Article medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 38:1834-1837 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.38.8.1834 |
| Popis: | Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|